Literature DB >> 12898240

Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema.

Takasuke Amizuka1, Hiroshi Shimizu, Yuichi Niida, Yunosuke Ogawa.   

Abstract

UNLABELLED: We studied the clinical and biochemical factors associated with surfactant dysfunction and factors affecting the responsiveness to exogenous surfactant among 27 neonates with haemorrhagic pulmonary oedema (HPE). HPE was defined as the presence of a large amount of blood-stained lung effluent and respiratory failure which was difficult to differentiate from respiratory distress syndrome. Among the neonates, 33% had very low birth weight, 96% were preterm, 70% were delivered by caesarean section, and 44% had delivery room intubation. The onset of HPE was at 1.5+/-0.1 h (mean +/- SEM) after birth. In 26 cases, surfactant was administered at 3.0+/-1.3 h after the onset of HPE. The concentrations of surfactant protein A (SP-A), disaturated phosphatidylcholine (DSPC), and albumin in the epithelial lining fluid were determined using the first lung effluent from the patients. The level of inhibitory activity against pulmonary surfactant in the effluent was determined in vitro. Surfactant inhibitory activity was associated with lower birth weight, earlier gestational age, delivery room intubation, earlier onset of HPE, and lower SP-A or DSPC concentration. A good response to exogenous surfactant, which was defined as ventilatory index <0.047 at 1 h after surfactant administration, was seen in 82% of cases, and was associated with lower serum albumin, lower birth weight, and earlier gestational age. Cases with higher DSPC concentration prior to surfactant administration and shorter interval between the onset of HPE and surfactant administration showed an immediate response to surfactant, followed by no increase in ventilatory index for 24 h after surfactant administration.
CONCLUSION: exogenous surfactant appeared to be a useful adjunctive therapy for overcoming surfactant inhibition and normalising the respiratory status of infants with haemorraghic pulmonary oedema. Surfactant treatment for this indication awaits further investigations including a randomised controlled study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898240     DOI: 10.1007/s00431-003-1276-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  [Radiologic study of hyaline membrane disease: 110 cases].

Authors:  F Bomsel
Journal:  J Radiol Electrol Med Nucl       Date:  1970-05

2.  Certain causes of neonatal death. IV. Massive pulmonary haemorrhage.

Authors:  J Fedrick; N R Butler
Journal:  Biol Neonate       Date:  1971

3.  Pulsating bubble technique for evaluating pulmonary surfactant.

Authors:  G Enhorning
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-08

4.  Enhancement of biophysical activity of lung surfactant extracts and phospholipid-apoprotein mixtures by surfactant protein A.

Authors:  A R Venkitaraman; S B Hall; J A Whitsett; R H Notter
Journal:  Chem Phys Lipids       Date:  1990-12       Impact factor: 3.329

5.  Pulmonary hemorrhage: clinical course and outcomes among very low-birth-weight infants.

Authors:  M Tomaszewska; E Stork; N M Minich; H Friedman; S Berlin; M Hack
Journal:  Arch Pediatr Adolesc Med       Date:  1999-07

6.  Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant.

Authors:  P B Pandit; K O'Brien; E Asztalos; E Colucci; M S Dunn
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-07       Impact factor: 5.747

7.  Monoclonal antibodies against human pulmonary surfactant apoproteins: specificity and application in immunoassay.

Authors:  Y Kuroki; Y Fukada; H Takahashi; T Akino
Journal:  Biochim Biophys Acta       Date:  1985-09-11

8.  Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study.

Authors:  J Garland; R Buck; M Weinberg
Journal:  Pediatrics       Date:  1994-11       Impact factor: 7.124

9.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial.

Authors:  M Hallman; T A Merritt; A L Jarvenpaa; B Boynton; F Mannino; L Gluck; T Moore; D Edwards
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

10.  Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.

Authors:  M Hallman; T A Merritt; T Akino; K Bry
Journal:  Am Rev Respir Dis       Date:  1991-12
View more
  11 in total

Review 1.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

2.  Respiratory support practices in infants born at term in the United Kingdom.

Authors:  Olie Chowdhury; Catherine J Wedderburn; Silke Lee; Simon Hannam; Anne Greenough
Journal:  Eur J Pediatr       Date:  2012-07-22       Impact factor: 3.183

3.  Surfactant therapy for maternal blood aspiration: an unusual cause of neonatal respiratory distress syndrome.

Authors:  Istemi Han Celik; Gamze Demirel; Fuat Emre Canpolat; Omer Erdeve; Ugur Dilmen
Journal:  Indian J Pediatr       Date:  2011-11-26       Impact factor: 1.967

Review 4.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

5.  Pulmonary Hemorrhage (PH) in Extremely Low Birth Weight (ELBW) Infants: Successful Treatment with Surfactant.

Authors:  Pradeep Suryawanshi; Rema Nagpal; Vaibhav Meshram; Nandini Malshe; Vijay Kalrao
Journal:  J Clin Diagn Res       Date:  2015-03-01

Review 6.  Guidelines for surfactant replacement therapy in neonates.

Authors:  Eugene H Ng; Vibhuti Shah
Journal:  Paediatr Child Health       Date:  2021-02-01       Impact factor: 2.253

7.  Surfactant for pulmonary haemorrhage in neonates.

Authors:  Abdul Aziz; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2020-02-03

Review 8.  Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?

Authors:  Emmanuel Lopez; Géraldine Gascoin; Cyril Flamant; Mona Merhi; Pierre Tourneux; Olivier Baud
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

9.  Use of therapeutic surfactant lavage in a preterm infant with massive pulmonary hemorrhage.

Authors:  Ino Kanavaki; Laszlo Vutskits; Peter C Rimensberger
Journal:  Clin Pract       Date:  2012-08-06

Review 10.  Surfactant replacement therapy: from biological basis to current clinical practice.

Authors:  Roland Hentschel; Kajsa Bohlin; Anton van Kaam; Hans Fuchs; Olivier Danhaive
Journal:  Pediatr Res       Date:  2020-01-11       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.